KR102785072B1 - 형질 세포 질환의 검출 방법 - Google Patents

형질 세포 질환의 검출 방법 Download PDF

Info

Publication number
KR102785072B1
KR102785072B1 KR1020207004033A KR20207004033A KR102785072B1 KR 102785072 B1 KR102785072 B1 KR 102785072B1 KR 1020207004033 A KR1020207004033 A KR 1020207004033A KR 20207004033 A KR20207004033 A KR 20207004033A KR 102785072 B1 KR102785072 B1 KR 102785072B1
Authority
KR
South Korea
Prior art keywords
splice variant
expression level
subject
biomarkers
myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207004033A
Other languages
English (en)
Korean (ko)
Other versions
KR20200029528A (ko
Inventor
마크 키드
아이그넛 드로즈도브
어빈 마크 모들린
Original Assignee
리퀴드 바이옵시 리서치 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리퀴드 바이옵시 리서치 엘엘씨 filed Critical 리퀴드 바이옵시 리서치 엘엘씨
Publication of KR20200029528A publication Critical patent/KR20200029528A/ko
Application granted granted Critical
Publication of KR102785072B1 publication Critical patent/KR102785072B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020207004033A 2017-07-21 2018-07-18 형질 세포 질환의 검출 방법 Active KR102785072B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535419P 2017-07-21 2017-07-21
US62/535,419 2017-07-21
PCT/US2018/042712 WO2019018540A1 (en) 2017-07-21 2018-07-18 METHODS FOR DETECTION OF PLASMOCYTE DYSGLOBULINEMIA

Publications (2)

Publication Number Publication Date
KR20200029528A KR20200029528A (ko) 2020-03-18
KR102785072B1 true KR102785072B1 (ko) 2025-03-20

Family

ID=63244986

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004033A Active KR102785072B1 (ko) 2017-07-21 2018-07-18 형질 세포 질환의 검출 방법

Country Status (14)

Country Link
US (2) US20190025311A1 (enExample)
EP (1) EP3655553B1 (enExample)
JP (1) JP7223741B2 (enExample)
KR (1) KR102785072B1 (enExample)
CN (1) CN111194356B (enExample)
AU (1) AU2018304242B2 (enExample)
BR (1) BR112020000791A2 (enExample)
CA (1) CA3067730A1 (enExample)
DK (1) DK3655553T3 (enExample)
ES (1) ES2916450T3 (enExample)
IL (1) IL271465B2 (enExample)
MX (1) MX2020000785A (enExample)
PL (1) PL3655553T3 (enExample)
WO (1) WO2019018540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916450T3 (es) 2017-07-21 2022-07-01 Liquid Biopsy Res Llc Método para la detección de discrasia de células plasmáticas
US20210108259A1 (en) 2019-10-10 2021-04-15 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
CN111349705A (zh) * 2020-03-18 2020-06-30 昆明医科大学 circASXL1作为肺癌诊断标志物及其运用
US20230203587A1 (en) * 2020-05-29 2023-06-29 Exosome Diagnostics, Inc. Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175753A1 (en) 2001-11-07 2003-09-18 Shaughnessy John D. Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
WO2011152884A2 (en) 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004313167A (ja) * 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用
CA3002661C (en) * 2004-05-21 2022-03-15 The Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
JP5904569B2 (ja) 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
US20120015906A1 (en) * 2009-01-02 2012-01-19 Shaughnessy Jr John D Uses of bortezomib in predicting survival in multiple myeloma patients
ES2916450T3 (es) 2017-07-21 2022-07-01 Liquid Biopsy Res Llc Método para la detección de discrasia de células plasmáticas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175753A1 (en) 2001-11-07 2003-09-18 Shaughnessy John D. Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
WO2011152884A2 (en) 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma

Also Published As

Publication number Publication date
KR20200029528A (ko) 2020-03-18
DK3655553T3 (da) 2022-06-20
WO2019018540A1 (en) 2019-01-24
US12366575B2 (en) 2025-07-22
US20190025311A1 (en) 2019-01-24
US20230022417A1 (en) 2023-01-26
IL271465B1 (en) 2023-04-01
PL3655553T3 (pl) 2022-09-26
BR112020000791A2 (pt) 2020-07-21
CA3067730A1 (en) 2019-01-24
EP3655553A1 (en) 2020-05-27
AU2018304242B2 (en) 2023-04-27
IL271465A (en) 2020-01-30
JP2020528274A (ja) 2020-09-24
ES2916450T3 (es) 2022-07-01
CN111194356B (zh) 2024-04-23
JP7223741B2 (ja) 2023-02-16
AU2018304242A1 (en) 2020-01-16
CN111194356A (zh) 2020-05-22
EP3655553B1 (en) 2022-03-23
MX2020000785A (es) 2020-11-06
IL271465B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
RU2721130C2 (ru) Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней
RU2719194C2 (ru) Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
KR101421326B1 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
US12366575B2 (en) Chemical compositions and methods of use
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
US12399179B2 (en) Chemical compositions and methods of use
JP2003259877A (ja) 肝線維症疾患マーカーおよびその利用
KR20100037637A (ko) Ｅｇｆｒ 억제제 치료에 대한 예측 마커
KR20190126812A (ko) 질환 진단용 바이오마커
KR102001153B1 (ko) 유방암 예후 예측용 조성물 및 방법
CN101827948A (zh) 检测鳞状细胞癌和腺癌及其高级别癌前病变的新分子标记
KR101804678B1 (ko) Bis 억제제 스크리닝용 마커, 이를 포함하는 스크리닝 키트 및 이를 이용한 bis 억제제 스크리닝 방법
JP2003250556A (ja) 糖代謝異常疾患マーカーおよびその利用
HK1084696A (en) Prognostic for hematological malignancy
KR20130024134A (ko) Ｇｃｐｓ 증후군 진단용 마이크로어레이 및 키트
HK1141723A (en) Methods and materials for identifying the origin of a carcinoma of unknown primary origin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210715

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240320

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241219

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250318

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250318

End annual number: 3

Start annual number: 1

PG1601 Publication of registration